The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria

Journal of Bioenergetics and Biomembranes

Volumn 46, Issue 5, 2014, Pages 389-394

  Macchioni, Lara ^a   Davidescu, Magdalena ^a   Roberti, Rita ^a   Corazzi, Lanfranco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Brain mitochondria; Bromopyruvate; Lonidamine; Respiration

Indexed keywords

3 BROMOPYRUVATE; ADENOSINE TRIPHOSPHATE; CITRININ; GLYCEROPHOSPHATE; LONIDAMINE; MALIC ACID; PYRUVIC ACID; SUCCINIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BROMOPYRUVATE; ENZYME INHIBITOR; INDAZOLE DERIVATIVE; PYRUVIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BIOENERGY; BRAIN MITOCHONDRION; CONTROLLED STUDY; ELECTRON TRANSPORT; ENZYME SYNTHESIS; IN VITRO STUDY; NONHUMAN; OXYGEN CONSUMPTION; RAT; RESPIRATORY CHAIN; ANIMAL; BRAIN; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MITOCHONDRION;

ANIMALIA; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; ENERGY METABOLISM; ENZYME INHIBITORS; INDAZOLES; MITOCHONDRIA; OXYGEN CONSUMPTION; PYRUVATES; RATS;

EID: 84918820349     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-014-9577-5     Document Type: Article

References (25)

1. Burdakov D, Ashcroft FM (2002) Shedding new light on brain metabolism and glial function. J Physiol 544:334
2. Corsi G, Palazzo G (1976) 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. J Med Chem 19:778–783
3. Davidescu M, Sciaccaluga M, Macchioni L, Angelini R, Lopalco P, Rambotti MG, Roberti R, Corcelli A, Castigli E, Corazzi L (2012) Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells. J Bioenerg Biomembr 44:51–60
4. Dell’Antone P (2009) Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med Chem 5:491–496
5. Du F, Zhu XH, Zhang Y, Friedman M, Zhang N, Ugurbil K, Chen W (2008) Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci USA 105:6409–6414
6. Floridi A, Paggi MG, D’Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A (1981) Effect of lonidamine on the enrgy metabolism of Ehrlich ascites tumor cells. Cancer Res 41:4661–4666
7. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909–3913
8. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91
9. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269–275
10. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL (2012) A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 44:163–170
11. Lai JC, Sheu KF, Carlson KC Jr (1985) Differences in some of the metabolic properties of mitochondria isolated from cerebral cortex and olfactory bulb of the rat. Brain Res 343:52–59
12. Liu Y, Fiskum G, Schubert D (2002) Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 80:780–787
13. Macchioni L, Davidescu M, Sciaccaluga M, Marchetti MC, Migliorati G, Coaccioli S, Roberti R, Corazzi L, Castigli E (2011a) Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. J Bioenerg Biomembr 43:507–518
14. 2 disposal in cardiolipin-enriched brain mitochondria is due to increased cytochrome c peroxidase activity. Biochim Biophys Acta 1811:203–208
15. Monni M, Corazzi L, Migliorati G, Roberti R (2000) Respiratory state and phosphatidylserine import in brain mitochondria in vitro. J Membr Biol 173:97–105
16. Pedersen PL (2007) Warburg, me and hexokinase 2: Multiple discoveries of key molecular events underlying one of cancer’s most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39:211–222
17. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FCL, Da Poian AT, Galina A (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417:717–726
18. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18:2537–2546
19. Rodrigues-Ferreira C, da Silva AP, Galina A (2012) Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase. J Bioenerg Biomembr 44:39–49
20. Rolfe DF, Brown GC (1997) Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 77:731–758
21. Schönfeld P, Reiser G (2006) Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria. J Biol Chem 281:7136–7142
22. Shoshan MC (2012) 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr 44:7–15
23. 2 generation in brain mitochondria. J Neurochem 100:650–663
24. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95–101
25. Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270